{"id":409256,"date":"2021-01-06T07:03:43","date_gmt":"2021-01-06T12:03:43","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409256"},"modified":"2021-01-06T07:03:43","modified_gmt":"2021-01-06T12:03:43","slug":"dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/","title":{"rendered":"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">BOSTON<\/span>, <span class=\"xn-chron\">Jan. 6, 2021<\/span> \/PRNewswire\/ &#8212; <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3026998-1&amp;h=3509842511&amp;u=https%3A%2F%2Fdewpointx.com%2F&amp;a=Dewpoint+Therapeutics\" rel=\"nofollow noopener noreferrer\">Dewpoint Therapeutics<\/a>, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy. Under the agreement, Dewpoint will receive an upfront payment and will be eligible to receive research, development, and sales milestones payments, totaling up to <span class=\"xn-money\">$239 million<\/span> should all milestones be achieved. Dewpoint will also be eligible to receive royalties on any approved products.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1283301\/Dewpoint_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1283301\/Dewpoint_Logo.jpg\" title=\"(PRNewsfoto\/Dewpoint Therapeutics)\" alt=\"(PRNewsfoto\/Dewpoint Therapeutics)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>DM1 is an inherited genetic disorder linked with the DMPK gene. People diagnosed with DM1 experience muscle loss and weakness, difficulty breathing, cataracts, heart conditions, intellectual disability, and early death. According to <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3026998-1&amp;h=2016627022&amp;u=https%3A%2F%2Frarediseases.org%2Frare-diseases%2Fdystrophy-myotonic%2F&amp;a=NORD\" rel=\"nofollow noopener noreferrer\">NORD<\/a>, DM1 affects approximately one in 8,000-20,000 people in the general population, with significant geographic and ethnic variation.<\/p>\n<p>&#8220;DM1 is a devastating disease for which there is no treatment that addresses its underlying cause, so we are eager to carry out our collaboration with Pfizer to accelerate the development of new treatments into this space,&#8221; said <span class=\"xn-person\">Ameet Nathwani<\/span>, M.D., Chief Executive Officer of Dewpoint. &#8220;We are excited about applying our platform to a wide array of diseases where biomolecular condensates may play a role in key disease pathways, as Dewpoint believes they do in DM1.&#8221;<\/p>\n<p>&#8220;The development of treatments for rare diseases, such as DM1, is a complex and rapidly evolving area of science, underscoring the importance of emerging research like this,&#8221; said <span class=\"xn-person\">Uwe Schoenbeck<\/span>, Senior Vice President and Chief Scientific Officer, External Science &amp; Innovation at Pfizer. &#8220;Through our combined expertise, we believe this collaboration has the potential to advance novel therapeutic solutions for patients in need.&#8221; <\/p>\n<p>\n        <b>About Biomolecular Condensates<br \/><\/b>Biomolecular condensates, formed through a process called phase separation, are membraneless droplets inside cells that facilitate molecular interactions and help cells perform vital functions. Condensates have been shown to play a critical role in key biological processes and in serious, intractable diseases across areas including neurodegeneration, cancer, inflammation, infectious disease, metabolic disease, and rare genetic disorders. The first condensates were observed more than 100 years ago. It is only in the last dozen years, though, that scientists\u2014including Dewpoint founders <span class=\"xn-person\">Tony Hyman<\/span> of the Max Planck Institute in Dresden and <span class=\"xn-person\">Rick Young<\/span> of the Whitehead Institute\u2014have begun to understand the dynamic nature and function of condensates. Dewpoint develops drugs that exploit this biology. Prior to the discovery of biomolecular condensate function, it was unknown how the right molecules could find each other at the right time to catalyze important processes in the crowded molecular environment of the cell.<\/p>\n<p>\n        <b>About Dewpoint Therapeutics<br \/><\/b>Dewpoint Therapeutics is the first company to apply the emerging understanding of\u00a0biomolecular condensates\u00a0to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates \u2014 including cancer, neurodegeneration, infectious disease, and metabolic disease. Dewpoint scientists work in <span class=\"xn-location\">Boston<\/span>, Dresden, and <span class=\"xn-location\">Berlin<\/span> to translate condensate biology into treatments for the toughest diseases.<\/p>\n<p>Learn more at\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3026998-1&amp;h=3394862216&amp;u=https%3A%2F%2Fdewpointx.com%2F&amp;a=dewpointx.com\" rel=\"nofollow noopener noreferrer\">dewpointx.com<\/a>, and follow us on\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3026998-1&amp;h=1931003333&amp;u=https%3A%2F%2Ftwitter.com%2Fdewpoint_tx&amp;a=Twitter\" rel=\"nofollow noopener noreferrer\">Twitter<\/a>\u00a0and\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3026998-1&amp;h=1928922514&amp;u=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fdewpointtherapeutics&amp;a=LinkedIn\" rel=\"nofollow noopener noreferrer\">LinkedIn<\/a>.<\/p>\n<p>Scientists or investors interested in biomolecular condensates can also visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3026998-1&amp;h=4068923847&amp;u=https%3A%2F%2Fcondensates.com%2F&amp;a=condensates.com\" rel=\"nofollow noopener noreferrer\">condensates.com<\/a>\u00a0for news and updates in the field.<\/p>\n<p>\n        <b>Contacts:<br \/><\/b><br \/>\n        <span class=\"xn-person\">Danielle Cantey<\/span><br \/>\n        <br \/>202-337-0808 <br \/><a target=\"_blank\" href=\"mailto:dcantey@gpg.com\" rel=\"nofollow noopener noreferrer\">dcantey@gpg.com<\/a><\/p>\n<p>Morgan Warners <br \/>202-337-0808 <br \/><a target=\"_blank\" href=\"mailto:mwarners@gpg.com\" rel=\"nofollow noopener noreferrer\">mwarners@gpg.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE38285&amp;sd=2021-01-06\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy-301201553.html\">http:\/\/www.prnewswire.com\/news-releases\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy-301201553.html<\/a><\/p>\n<p>SOURCE  Dewpoint Therapeutics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE38285&amp;Transmission_Id=202101060700PR_NEWS_USPR_____NE38285&amp;DateId=20210106\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire BOSTON, Jan. 6, 2021 \/PRNewswire\/ &#8212; Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy. Under the agreement, Dewpoint will receive an upfront payment and will be eligible to receive research, development, and sales milestones payments, totaling up to $239 million should all milestones be achieved. Dewpoint will also be eligible to receive royalties on any approved products. DM1 is an inherited genetic disorder linked with the DMPK gene. People diagnosed with DM1 experience muscle loss and weakness, difficulty breathing, cataracts, heart conditions, intellectual &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409256","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BOSTON, Jan. 6, 2021 \/PRNewswire\/ &#8212; Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy. Under the agreement, Dewpoint will receive an upfront payment and will be eligible to receive research, development, and sales milestones payments, totaling up to $239 million should all milestones be achieved. Dewpoint will also be eligible to receive royalties on any approved products. DM1 is an inherited genetic disorder linked with the DMPK gene. People diagnosed with DM1 experience muscle loss and weakness, difficulty breathing, cataracts, heart conditions, intellectual &hellip; Continue reading &quot;Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T12:03:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1283301\/Dewpoint_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy\",\"datePublished\":\"2021-01-06T12:03:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/\"},\"wordCount\":578,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1283301\\\/Dewpoint_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/\",\"name\":\"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1283301\\\/Dewpoint_Logo.jpg\",\"datePublished\":\"2021-01-06T12:03:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1283301\\\/Dewpoint_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1283301\\\/Dewpoint_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/","og_locale":"en_US","og_type":"article","og_title":"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy - Market Newsdesk","og_description":"PR Newswire BOSTON, Jan. 6, 2021 \/PRNewswire\/ &#8212; Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and one of two types of myotonic dystrophy. Under the agreement, Dewpoint will receive an upfront payment and will be eligible to receive research, development, and sales milestones payments, totaling up to $239 million should all milestones be achieved. Dewpoint will also be eligible to receive royalties on any approved products. DM1 is an inherited genetic disorder linked with the DMPK gene. People diagnosed with DM1 experience muscle loss and weakness, difficulty breathing, cataracts, heart conditions, intellectual &hellip; Continue reading \"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T12:03:43+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1283301\/Dewpoint_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy","datePublished":"2021-01-06T12:03:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/"},"wordCount":578,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1283301\/Dewpoint_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/","name":"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1283301\/Dewpoint_Logo.jpg","datePublished":"2021-01-06T12:03:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1283301\/Dewpoint_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1283301\/Dewpoint_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dewpoint-announces-collaboration-with-pfizer-to-develop-potential-therapies-for-a-rare-form-of-muscular-dystrophy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dewpoint Announces Collaboration with Pfizer to Develop Potential Therapies for a Rare Form of Muscular Dystrophy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409256"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409256\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}